{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T09:19:55Z","timestamp":1773134395170,"version":"3.50.1"},"reference-count":100,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Erika J. Glazer Family Foundation","award":["U54CA260591"],"award-info":[{"award-number":["U54CA260591"]}]},{"name":"Erika J. Glazer Family Foundation","award":["75N91019D00024"],"award-info":[{"award-number":["75N91019D00024"]}]},{"name":"Erika J. Glazer Family Foundation","award":["75N91021F00001"],"award-info":[{"award-number":["75N91021F00001"]}]},{"name":"Erika J. Glazer Family Foundation","award":["21X091"],"award-info":[{"award-number":["21X091"]}]},{"name":"Sapient Bioanalytics, LLC. U.S, National Cancer Institute (NCI)","award":["U54CA260591"],"award-info":[{"award-number":["U54CA260591"]}]},{"name":"Sapient Bioanalytics, LLC. U.S, National Cancer Institute (NCI)","award":["75N91019D00024"],"award-info":[{"award-number":["75N91019D00024"]}]},{"name":"Sapient Bioanalytics, LLC. U.S, National Cancer Institute (NCI)","award":["75N91021F00001"],"award-info":[{"award-number":["75N91021F00001"]}]},{"name":"Sapient Bioanalytics, LLC. U.S, National Cancer Institute (NCI)","award":["21X091"],"award-info":[{"award-number":["21X091"]}]},{"name":"Cedars Sinai institutional funds","award":["U54CA260591"],"award-info":[{"award-number":["U54CA260591"]}]},{"name":"Cedars Sinai institutional funds","award":["75N91019D00024"],"award-info":[{"award-number":["75N91019D00024"]}]},{"name":"Cedars Sinai institutional funds","award":["75N91021F00001"],"award-info":[{"award-number":["75N91021F00001"]}]},{"name":"Cedars Sinai institutional funds","award":["21X091"],"award-info":[{"award-number":["21X091"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Herein, we review established clinical use cases for SARS-CoV-2 antibody measures, which include diagnosis of recent prior infection, isolating high titer convalescent plasma, diagnosing multisystem inflammatory syndrome in children (MIS-C), and booster dosing in the immunosuppressed and other populations. We then address whether an antibody correlate of protection (CoP) for SARS-CoV-2 has been successfully defined with the following considerations: Antibody responses in the immunocompetent, vaccine type, variants, use of binding antibody tests vs. neutralization tests, and endpoint measures. In the transition from the COVID-19 pandemic to endemic, there has been much interest in defining an antibody CoP. Due to the high mutability of respiratory viruses and our current knowledge of SARS-CoV-2 variants defining a CoP for prevention of infection is unrealistic. However, a CoP may be defined for prevention of severe disease requiring hospitalization and\/or death. Most SARS-CoV-2 CoP research has focused on neutralization measurements. However, there can be significant differences in neutralization test methods, and disparate responses to new variants depending on format. Furthermore, neutralization assays are often impractical for high throughput applications (e.g., assessing humoral immune response in populations or large cohorts). Nevertheless, CoP studies using neutralization measures are reviewed to determine where there is consensus. Alternatively, binding antibody tests could be used to define a CoP. Binding antibody assays tend to be highly automatable, high throughput, and therefore practical for large population applications. Again, we review studies for consensus on binding antibody responses to vaccines, focusing on standardized results. Binding antibodies directed against the S1 receptor binding domain (S1-RBD) of the viral spike protein can provide a practical, indirect measure of neutralization. Initially, a response for S1-RBD antibodies may be selected that reflects the peak response in immunocompetent populations and may serve as a target for booster dosing in the immunocompromised. From existing studies reporting peak S1-RBD responses in standardized units, an approximate range of 1372\u20132744 BAU\/mL for mRNA and recombinant protein vaccines was extracted that could serve as an initial CoP target. This target would need to be confirmed and potentially adjusted for updated vaccines, and almost certainly for other vaccine formats (i.e., viral vector). Alternatively, a threshold or response could be defined based on outcomes over time (i.e., prevention of severe disease). We also discuss the precedent for clinical measurement of antibodies for vaccine-preventable diseases (e.g., hepatitis B). Lastly, cellular immunity is briefly addressed for its importance in the nature and durability of protection.<\/jats:p>","DOI":"10.3390\/vaccines11111644","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T06:20:16Z","timestamp":1698301216000},"page":"1644","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Clinical Utility of SARS-CoV-2 Serological Testing and Defining a Correlate of Protection"],"prefix":"10.3390","volume":"11","author":[{"given":"Kimia","family":"Sobhani","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4977-036X","authenticated-orcid":false,"given":"Susan","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8179-4145","authenticated-orcid":false,"given":"Raquel A.","family":"Binder","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5083-8640","authenticated-orcid":false,"given":"Nicholas J.","family":"Mantis","sequence":"additional","affiliation":[{"name":"Wadsworth Center, New York State Department of Health, Albany, NY 12201, USA"},{"name":"Department of Biomedical Sciences, School of Public Health, University at Albany, Albany, NY 12222, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Crawford","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, NY 11549, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nkemakonam","family":"Okoye","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, NY 11549, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1646-2974","authenticated-orcid":false,"given":"Jonathan G.","family":"Braun","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA"},{"name":"F. Widjaja Inflammatory Bowel Disease Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7582-3218","authenticated-orcid":false,"given":"Sandy","family":"Joung","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minhao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Lozanski","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher L.","family":"King","sequence":"additional","affiliation":[{"name":"Department of Pathology, Case Western Reserve University and Veterans Affairs Research Service, Cleveland, OH 44106, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Roback","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas A.","family":"Granger","sequence":"additional","affiliation":[{"name":"Institute for Interdisciplinary Salivary Bioscience Research, University of California Irvine, Irvine, CA 92697, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh B.","family":"Boppana","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Department of Microbiology, Heersink School of Medicine, UAB, Birmingham, AL 35233, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy B.","family":"Karger","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.arcmed.2020.05.012","article-title":"Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2","volume":"51","author":"Satarker","year":"2020","journal-title":"Arch. Med. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.abc6952","article-title":"A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","article-title":"Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses","volume":"23","author":"Chen","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1126\/science.abj3321","article-title":"Broad betacoronavirus neutralization by a stem helix-specific human antibody","volume":"373","author":"Pinto","year":"2021","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1126\/science.abq3773","article-title":"Broadly neutralizing antibodies target the coronavirus fusion peptide","volume":"377","author":"Dacon","year":"2022","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.abq2679","article-title":"ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies","volume":"377","author":"Low","year":"2022","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Meyers, J., Windau, A., Schmotzer, C., Saade, E., Noguez, J., Stempak, L., and Zhang, X. (2022). SARS-CoV-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassays. Diagn. Microbiol. Infect. Dis., 104, (In English).","DOI":"10.1101\/2022.01.24.22269699"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"752003","DOI":"10.3389\/fimmu.2021.752003","article-title":"Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants","volume":"12","author":"Shrestha","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2220582","DOI":"10.1080\/22221751.2023.2220582","article-title":"SARS-CoV-2 spike S2-specific neutralizing antibodies","volume":"12","author":"Li","year":"2023","journal-title":"Emerg. Microbes Infect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"eabn3715","DOI":"10.1126\/scitranslmed.abn3715","article-title":"SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies","volume":"14","author":"Ng","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Halfmann, P.J., Frey, S.J., Loeffler, K., Kuroda, M., Maemura, T., Armbrust, T., Yang, J.E., Hou, Y.J., Baric, R., and Wright, E.R. (2022). Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses. EBioMedicine, 86, (In English).","DOI":"10.1016\/j.ebiom.2022.104341"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/s41422-022-00746-3","article-title":"A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein","volume":"32","author":"Pang","year":"2022","journal-title":"Cell Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"104490","DOI":"10.1016\/j.meegid.2020.104490","article-title":"Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2","volume":"89","author":"Kaur","year":"2021","journal-title":"Infect. Genet. Evol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Bai, Z., Cao, Y., Liu, W., and Li, J. (2021). The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation. Viruses, 13, (In English).","DOI":"10.3390\/v13061115"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Naqvi, A.A.T., Fatima, K., Mohammad, T., Fatima, U., Singh, I.K., Singh, A., Atif, S.M., Hariprasad, G., Hasan, G.M., and Hassan, M.I. (2020). Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim. Biophys. Acta Mol. Basis Dis., 1866, (In English).","DOI":"10.1016\/j.bbadis.2020.165878"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zhang, B., Tian, J., Zhang, Q., Xie, Y., Wang, K., Qiu, S., Lu, K., and Liu, Y. (2022). Comparing the Nucleocapsid Proteins of Human Coronaviruses: Structure, Immunoregulation, Vaccine, and Targeted Drug. Front. Mol. Biosci., 9, (In English).","DOI":"10.3389\/fmolb.2022.761173"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1093\/cid\/ciab219","article-title":"Estimated Half-Life of SARS-CoV-2 Anti-Spike Antibodies More Than Double the Half-Life of Anti-nucleocapsid Antibodies in Healthcare Workers","volume":"73","author":"Gruwier","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"eabc8413","DOI":"10.1126\/sciimmunol.abc8413","article-title":"The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients","volume":"5","author":"Premkumar","year":"2020","journal-title":"Sci. Immunol."},{"key":"ref_20","unstructured":"IDSA (2022, October 10). Antibody Testing. Available online: https:\/\/www.idsociety.org\/covid-19-real-time-learning-network\/diagnostics\/antibody-testing\/."},{"key":"ref_21","unstructured":"US FDA (2022, October 10). EUA Authorized Serology Test Performance, Available online: https:\/\/www.fda.gov\/medical-devices\/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices\/eua-authorized-serology-test-performance."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Fong, Y., Huang, Y., Benkeser, D., Carpp, L.N., \u00c1\u00f1ez, G., Woo, W., McGarry, A., Dunkle, L.M., Cho, I., and Houchens, C.R. (2022). Immune Correlates Analysis of the PREVENT-19 COVID-19 Vaccine Efficacy Clinical Trial. medRxiv.","DOI":"10.1101\/2022.06.22.22276362"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41564-022-01262-1","article-title":"Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial","volume":"7","author":"Fong","year":"2022","journal-title":"Nat. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico","volume":"386","author":"Dunkle","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41467-022-35768-3","article-title":"Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial","volume":"14","author":"Fong","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Deeba, E., Krashias, G., Constantinou, A., Koptides, D., Lambrianides, A., and Christodoulou, C. (2022). Evaluation of S1RBD-Specific IgG Antibody Responses following COVID-19 Vaccination in Healthcare Professionals in Cyprus: A Comparative Look between the Vaccines of Pfizer-BioNTech and AstraZeneca. Microorganisms, 10, (In English).","DOI":"10.3390\/microorganisms10050967"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ijid.2022.06.008","article-title":"Lasting SARS-CoV-2 specific IgG Antibody response in health care workers from Venezuela, 6 months after vaccination with Sputnik, V","volume":"122","author":"Claro","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijid.2022.05.061","article-title":"Longitudinal dynamics of SARS-CoV-2 anti-receptor binding domain IgG antibodies in a wide population of health care workers after BNT162b2 vaccination","volume":"122","author":"Bordi","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Lo Sasso, B., Giglio, R.V., Vidali, M., Scazzone, C., Bivona, G., Gambino, C.M., Ciaccio, A.M., Agnello, L., and Ciaccio, M. (2021). Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine. Diagnostics, 11, (In English).","DOI":"10.3390\/diagnostics11071135"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/cid\/ciab381","article-title":"Age-dependent Immune Response to the Biontech\/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination","volume":"73","author":"Moskorz","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"11652","DOI":"10.3389\/av.2023.11652","article-title":"Study of anti-S1-protein IgG antibody levels as potential correlates of protection against breakthrough infection with SARS-CoV-2 Omicron BA.1 and BA.2 variants","volume":"67","author":"Kajanova","year":"2023","journal-title":"Acta Virol."},{"key":"ref_34","unstructured":"(2022, November 03). Interim Guidelines for COVID-19 Antibody Testing, CDC, Available online: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/lab\/resources\/antibody-tests-guidelines.html#anchor_1616006658343."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S1473-3099(22)00345-0","article-title":"Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: A population-based observational study","volume":"22","author":"McMenamin","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/clinchem\/hvab051","article-title":"AACC Practical Recommendations for Implementing and Interpreting SARS-CoV-2 Emergency Use Authorization and Laboratory-Developed Test Serologic Testing in Clinical Laboratories","volume":"67","author":"Zhang","year":"2021","journal-title":"Clin. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1128\/JVI.73.1.51-54.1999","article-title":"Spontaneous mutation rate of measles virus: Direct estimation based on mutations conferring monoclonal antibody resistance","volume":"73","author":"Schrag","year":"1999","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.celrep.2015.04.054","article-title":"Mutational Analysis of Measles Virus Suggests Constraints on Antigenic Variation of the Glycoproteins","volume":"11","author":"Fulton","year":"2015","journal-title":"Cell Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100225","DOI":"10.1016\/j.xcrm.2021.100225","article-title":"Serotypic evolution of measles virus is constrained by multiple co-dominant B cell epitopes on its surface glycoproteins","volume":"2","author":"Nace","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_40","unstructured":"CDC (2022, November 03). Selecting Viruses for the Seasonal Influenza Vaccine, Available online: https:\/\/www.cdc.gov\/flu\/prevent\/vaccine-selection.htm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1128\/JVI.80.7.3675-3678.2006","article-title":"Comparison of the mutation rates of human influenza A and B viruses","volume":"80","author":"Nobusawa","year":"2006","journal-title":"J. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrmicro.2017.118","article-title":"The evolution of seasonal influenza viruses","volume":"16","author":"Petrova","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_43","first-page":"1","article-title":"CDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management","volume":"62","author":"Schillie","year":"2013","journal-title":"Morb. Mortal. Wkly. Rep. (MMWR)"},{"key":"ref_44","first-page":"1","article-title":"A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: Immunization of infants, children, and adolescents","volume":"54","author":"Mast","year":"2005","journal-title":"MMWR Recomm. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1086\/314578","article-title":"What level of hepatitis B antibody is protective?","volume":"179","author":"Jack","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e1500","DOI":"10.1542\/peds.2013-2940","article-title":"Duration of protection after infant hepatitis B vaccination series","volume":"133","author":"Middleman","year":"2014","journal-title":"Pediatrics"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/jiv750","article-title":"Long-term Protection After Hepatitis B Vaccine","volume":"214","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/cid\/cir270","article-title":"Hepatitis B and the need for a booster dose","volume":"53","author":"Leuridan","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.vaccine.2016.02.063","article-title":"Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection","volume":"34","author":"Ng","year":"2016","journal-title":"Vaccine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SAR.S.; and uninfected controls","volume":"584","author":"Tan","year":"2020","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"840126","DOI":"10.3389\/fimmu.2022.840126","article-title":"SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity","volume":"13","author":"Steiner","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/infdis\/jiv748","article-title":"Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose","volume":"214","author":"Bruce","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41564-021-01051-2","article-title":"Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection","volume":"7","author":"Yang","year":"2022","journal-title":"Nat. Microbiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"829665","DOI":"10.3389\/fimmu.2022.829665","article-title":"Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Chansaenroj, J., Yorsaeng, R., Puenpa, J., Wanlapakorn, N., Chirathaworn, C., Sudhinaraset, N., Sripramote, M., Chalongviriyalert, P., Jirajariyavej, S., and Kiatpanabhikul, P. (2022). Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients. PLoS ONE, 17, (In English).","DOI":"10.1371\/journal.pone.0267102"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e059994","DOI":"10.1136\/bmjopen-2021-059994","article-title":"Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: A longitudinal cohort analysis","volume":"12","author":"Ebinger","year":"2022","journal-title":"BMJ Open"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMp2211314","article-title":"A Covid-19 Milestone Attained\u2014A Correlate of Protection for Vaccines","volume":"387","author":"Gilbert","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1038\/s41467-022-31556-1","article-title":"Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs","volume":"13","author":"Bekliz","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_59","unstructured":"World Health Organization (2022, November 03). WHO\/BS.2020.2403 Establishment of the WHO International Standard and Reference Panel for Anti-SARS-CoV-2 Antibody. Available online: https:\/\/www.who.int\/publications\/m\/item\/WHO-BS-2020.2403."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/S2666-5247(21)00266-4","article-title":"WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: Call for urgent action by the scientific community","volume":"3","author":"Knezevic","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(21)00527-4","article-title":"WHO International Standard for anti-SARS-CoV-2 immunoglobulin","volume":"397","author":"Kristiansen","year":"2021","journal-title":"Lancet"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.13091","article-title":"Correlates of protection against SARS-CoV-2 infection and COVID-19 disease","volume":"310","author":"Goldblatt","year":"2022","journal-title":"Immunol. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Grunau, B., Prusinkiewicz, M., Asamoah-Boaheng, M., Golding, L., Lavoie, P.M., Petric, M., Levett, P.N., Haig, S., Barakauskas, V., and Karim, M.E. (2022). Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals. Microbiol. Spectr., 10, (In English).","DOI":"10.1128\/spectrum.01315-22"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.vaccine.2021.12.006","article-title":"Towards a population-based threshold of protection for COVID-19 vaccines","volume":"40","author":"Goldblatt","year":"2022","journal-title":"Vaccine"},{"key":"ref_65","unstructured":"FDA (2023). FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect against Currently Circulating Variants, FDA."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Hanson, K.E., Caliendo, A.M., Arias, C.A., Englund, J.A., Hayden, M.K., Lee, M.J., Loeb, M., Patel, R., Altayar, O., and El Alayli, A. (2020). Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19:Serologic Testing. Clin. Infect. Dis., (In English).","DOI":"10.1093\/cid\/ciaa1343"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41563-020-00906-z","article-title":"Diagnostics for SARS-CoV-2 infections","volume":"20","author":"Kevadiya","year":"2021","journal-title":"Nat. Mater."},{"key":"ref_68","unstructured":"Jacqueline, A., and O\u2019Shaughnessy, P.D. (2021). Convalescent Plasma EUA Letter of Authorization, FDA."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMe2035678","article-title":"(A Little) Clarity on Convalescent Plasma for Covid-19","volume":"384","author":"Katz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJMoa2103784","article-title":"Early Convalescent Plasma for High-Risk Outpatients with Covid-19","volume":"385","author":"Korley","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMc2119407","article-title":"Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant","volume":"386","author":"Takashita","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMc2201933","article-title":"Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA","volume":"386","author":"Takashita","year":"2022","journal-title":"2. N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41586-022-04690-5","article-title":"Defining the risk of SARS-CoV-2 variants on immune protection","volume":"605","author":"DeGrace","year":"2022","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-020-1054-6","article-title":"Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection","volume":"26","author":"Carter","year":"2020","journal-title":"Nat. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1172\/JCI141113","article-title":"Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children","volume":"130","author":"Lee","year":"2020","journal-title":"J. Clin. Invest."},{"key":"ref_76","unstructured":"(2022, November 03). Multisystem Inflammatory Syndrome in Children (MIS-C) Interim Guidance, AAP. Available online: https:\/\/www.aap.org\/en\/pages\/2019-novel-coronavirus-covid-19-infections\/clinical-guidance\/multisystem-inflammatory-syndrome-in-children-mis-c-interim-guidance\/."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/s41564-021-00947-3","article-title":"Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom","volume":"6","author":"Wei","year":"2021","journal-title":"Nat. Microbiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.7326\/M21-1757","article-title":"Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2: A Prospective Cohort Study","volume":"174","author":"Deepak","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/annrheumdis-2021-220626","article-title":"Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression","volume":"80","author":"Prendecki","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: Interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1111\/ajt.16607","article-title":"Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients","volume":"21","author":"Marinaki","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e2136030","DOI":"10.1001\/jamanetworkopen.2021.36030","article-title":"Assessment of 4 Doses of SARS-CoV-2 Messenger RNA-Based Vaccine in Recipients of a Solid Organ Transplant","volume":"4","author":"Kamar","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_83","unstructured":"(2022, October 10). Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-announce-omicron-adapted-covid-19."},{"key":"ref_84","unstructured":"(2022, October 10). Moderna Announces Bivalent Booster Mrna-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants Ba.4 And Ba.5. Available online: https:\/\/investors.modernatx.com\/news\/news-details\/2022\/Moderna-Announces-Bivalent-Booster-mRNA-1273.214-Demonstrates-Potent-Neutralizing-Antibody-Response-Against-Omicron-Subvariants-BA.4-And-BA.5\/default.aspx."},{"key":"ref_85","unstructured":"(2022, October 10). UNDP. Available online: https:\/\/data.undp.org\/vaccine-equity\/."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Jacobs, E.T., Cordova-Marks, F.M., Farland, L.V., Ernst, K.C., Andrews, J.G., Vu, S., Heslin, K.M., Catalfamo, C., Chen, Z., and Pogreba-Brown, K. (2023). Understanding low COVID-19 booster uptake among US adults. Vaccine, (In English).","DOI":"10.1016\/j.vaccine.2023.08.080"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41591-022-02185-4","article-title":"A survey of COVID-19 vaccine acceptance across 23 countries in 2022","volume":"29","author":"Lazarus","year":"2023","journal-title":"Nat. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/08830185.2021.1929205","article-title":"Antibody Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development","volume":"41","author":"Mallano","year":"2022","journal-title":"Int. Rev. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"811","DOI":"10.7326\/M20-7547","article-title":"Antibody Response After SARS-CoV-2 Infection and Implications for Immunity: A Rapid Living Review","volume":"174","author":"Helfand","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_90","unstructured":"CDC (2023, August 18). In Vitro Diagnostics EUAs\u2014Serology and Other Adaptive Immune Response Tests for SARS-CoV-2, Available online: https:\/\/www.fda.gov\/medical-devices\/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices\/in-vitro-diagnostics-euas-serology-and-other-adaptive-immune-response-tests-sars-cov-2."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJMc2206576","article-title":"Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5","volume":"387","author":"Hachmann","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_92","unstructured":"Roche Diagnostics (2023, September 19). Detecting Coronavirus Variants with Roche Assays. Available online: https:\/\/diagnostics.roche.com\/us\/en\/article-listing\/assays-detect-coronavirus-variants.html."},{"key":"ref_93","unstructured":"(2022, October 10). Predicted Impact of Variants on Abbott\u2019s SARS-CoV-2\/COVID-19 Diagnostic Tests Abbott. Available online: https:\/\/www.molecular.abbott\/sal\/AMD.15594%20Cross%20Division%20COVID%20Variant%20Tech%20Brief_Web.pdf."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41467-021-27674-x","article-title":"Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts","volume":"13","author":"Kundu","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/s41587-022-01347-6","article-title":"Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR","volume":"40","author":"Schwarz","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"eabi6950","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory B cell responses in SARS-CoV-2 na\u00efve and recovered individuals following mRNA vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41586-022-04778-y","article-title":"Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost","volume":"607","author":"Muecksch","year":"2022","journal-title":"Nature"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/11\/1644\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:12:12Z","timestamp":1760130732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/11\/1644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":100,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["vaccines11111644"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11111644","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]}}}